Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We p...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/12/1857 |
| _version_ | 1827661469654712320 |
|---|---|
| author | Alessandro Rizzo Antonio Cusmai Raffaella Massafra Samantha Bove Maria Colomba Comes Annarita Fanizzi Lucia Rinaldi Silvana Acquafredda Gennaro Gadaleta-Caldarola Donato Oreste Alfredo Zito Francesco Giotta Vito Lorusso Gennaro Palmiotti |
| author_facet | Alessandro Rizzo Antonio Cusmai Raffaella Massafra Samantha Bove Maria Colomba Comes Annarita Fanizzi Lucia Rinaldi Silvana Acquafredda Gennaro Gadaleta-Caldarola Donato Oreste Alfredo Zito Francesco Giotta Vito Lorusso Gennaro Palmiotti |
| author_sort | Alessandro Rizzo |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We performed a meta-analysis aimed at assessing the Odds Ratio (OR) of the pathological complete response (pCR) rate in trials assessing neoadjuvant chemoimmunotherapy in TNBC. According to our results, the use of neoadjuvant chemoimmunotherapy was associated with higher pCR (OR 1.95; 95% Confidence Intervals, 1.27–2.99). In addition, we highlighted that this benefit was observed regardless of PD-L1 status since the analysis reported a statistically significant and clinically meaningful benefit in both PD-L1 positive and PD-L1 negative patients. These findings further support the exploration of the role of ICIs plus chemotherapy in early-stage TNBC, given the potentially meaningful clinical impact of these agents. Further studies aimed at more deeply investigating this emerging topic in breast cancer immunotherapy are warranted. |
| first_indexed | 2024-03-10T00:10:48Z |
| format | Article |
| id | doaj.art-1d10e54901184395b763dfcdee2f06db |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T00:10:48Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-1d10e54901184395b763dfcdee2f06db2023-11-23T16:00:26ZengMDPI AGCells2073-44092022-06-011112185710.3390/cells11121857Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-AnalysisAlessandro Rizzo0Antonio Cusmai1Raffaella Massafra2Samantha Bove3Maria Colomba Comes4Annarita Fanizzi5Lucia Rinaldi6Silvana Acquafredda7Gennaro Gadaleta-Caldarola8Donato Oreste9Alfredo Zito10Francesco Giotta11Vito Lorusso12Gennaro Palmiotti13Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Fisica Sanitaria, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Fisica Sanitaria, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Fisica Sanitaria, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Fisica Sanitaria, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyMedical Oncology Unit, ‘Mons. R. Dimiccoli’ Hospital, Barletta (BT), Azienda Sanitaria Locale Barletta, 76121 Barletta, ItalyRadiology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Giovanni Paolo II, 70124 Bari, ItalyUnità Operativa Complessa di Anatomia Patologica, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyUnità Operativa Complessa di Oncologia Medica, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyUnità Operativa Complessa di Oncologia Medica, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyStruttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello”, IRCCS, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, ItalyImmune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We performed a meta-analysis aimed at assessing the Odds Ratio (OR) of the pathological complete response (pCR) rate in trials assessing neoadjuvant chemoimmunotherapy in TNBC. According to our results, the use of neoadjuvant chemoimmunotherapy was associated with higher pCR (OR 1.95; 95% Confidence Intervals, 1.27–2.99). In addition, we highlighted that this benefit was observed regardless of PD-L1 status since the analysis reported a statistically significant and clinically meaningful benefit in both PD-L1 positive and PD-L1 negative patients. These findings further support the exploration of the role of ICIs plus chemotherapy in early-stage TNBC, given the potentially meaningful clinical impact of these agents. Further studies aimed at more deeply investigating this emerging topic in breast cancer immunotherapy are warranted.https://www.mdpi.com/2073-4409/11/12/1857breast cancerpembrolizumabatezolizumabdurvalumabimmunotherapyneoadjuvant |
| spellingShingle | Alessandro Rizzo Antonio Cusmai Raffaella Massafra Samantha Bove Maria Colomba Comes Annarita Fanizzi Lucia Rinaldi Silvana Acquafredda Gennaro Gadaleta-Caldarola Donato Oreste Alfredo Zito Francesco Giotta Vito Lorusso Gennaro Palmiotti Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis Cells breast cancer pembrolizumab atezolizumab durvalumab immunotherapy neoadjuvant |
| title | Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis |
| title_full | Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis |
| title_fullStr | Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis |
| title_full_unstemmed | Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis |
| title_short | Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis |
| title_sort | pathological complete response to neoadjuvant chemoimmunotherapy for early triple negative breast cancer an updated meta analysis |
| topic | breast cancer pembrolizumab atezolizumab durvalumab immunotherapy neoadjuvant |
| url | https://www.mdpi.com/2073-4409/11/12/1857 |
| work_keys_str_mv | AT alessandrorizzo pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT antoniocusmai pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT raffaellamassafra pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT samanthabove pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT mariacolombacomes pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT annaritafanizzi pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT luciarinaldi pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT silvanaacquafredda pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT gennarogadaletacaldarola pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT donatooreste pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT alfredozito pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT francescogiotta pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT vitolorusso pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis AT gennaropalmiotti pathologicalcompleteresponsetoneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcanceranupdatedmetaanalysis |